P
EW icon

&Partners’s Edwards Lifesciences EW Stock Holding History

&Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Sell
24,525
-348
-1% -$28.7K 0.01% 917
2025
Q4 		$2.12M Buy
24,873
+806
+3% +$66.1K 0.01% 827
2025
Q3 		$1.86M Buy
24,067
+4,508
+23% +$352K 0.01% 786
2025
Q2 		$1.53M Buy
19,559
+8,799
+82% +$656K 0.01% 783
2025
Q1 		$766K Buy
10,760
+2,600
+32% +$186K 0.01% 929
2024
Q4 		$609K Buy
8,160
+3,496
+75% +$245K 0.01% 992
2024
Q3 		$308K Buy
4,664
+1,351
+41% +$98.2K 0.01% 1088
2024
Q2 		$306K Buy
+3,313
New +$293K 0.01% 708

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

&Partners's EW Position: Q1 2026 in Review

&Partners reduced its Edwards Lifesciences (EW) stake by 1.4% in Q1 2026, selling an estimated $28.7K and leaving 24,525 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #917.

&Partners first reported a position in EW in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.12M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • &Partners held 24,525 shares of Edwards Lifesciences worth $1.96M as of Q1 2026.
  • &Partners sold 348 Edwards Lifesciences shares in Q1 2026, an estimated $28.7K.
  • Edwards Lifesciences made up 0.01% of &Partners's portfolio in Q1 2026, its #917 holding.
  • &Partners first reported a position in Edwards Lifesciences in Q2 2024 and has held it in 8 quarters since.
  • &Partners's Edwards Lifesciences position peaked at $2.12M in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.